Marty
Well-known member
FDA approves generic version of Lovenox.
The AP (7/23) reported that "Momenta Pharmaceuticals Inc. said Friday the US Food and Drug Administration approved its generic version of Sanofi-Aventis SA's Lovenox [enoxaparin], an injected drug for preventing life-threatening blood clots."
The Los Angeles Times (7/24, Zajac) reported that "in its decision, the FDA also rejected an argument by Lovenox's maker, Sanofi-Aventis, that its drug, which is made from sugar molecules found in heparin, a substance derived from pig intestines, is too complex to be copied with precision by makers of generic versions of the medication."
The New York Times (7/23, Pollack) "Prescriptions" blog reported that "Momenta, which applied for approval of its drug five years ago, claims its technology can accurately characterize such complex mixtures." The Wall Street Journal (7/24, Mundy), the Boston Globe (7/24), and MedPage Today (7/23, Neale) also covered the story
The AP (7/23) reported that "Momenta Pharmaceuticals Inc. said Friday the US Food and Drug Administration approved its generic version of Sanofi-Aventis SA's Lovenox [enoxaparin], an injected drug for preventing life-threatening blood clots."
The Los Angeles Times (7/24, Zajac) reported that "in its decision, the FDA also rejected an argument by Lovenox's maker, Sanofi-Aventis, that its drug, which is made from sugar molecules found in heparin, a substance derived from pig intestines, is too complex to be copied with precision by makers of generic versions of the medication."
The New York Times (7/23, Pollack) "Prescriptions" blog reported that "Momenta, which applied for approval of its drug five years ago, claims its technology can accurately characterize such complex mixtures." The Wall Street Journal (7/24, Mundy), the Boston Globe (7/24), and MedPage Today (7/23, Neale) also covered the story